Laekna, Inc. (HK:2105) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Laekna, Inc. has announced the initiation of subcutaneous dosing in their Phase I clinical trial of LAE102, a promising monoclonal antibody for obesity treatment. The trial is progressing well, with early signs of target engagements and expected biomarker changes already observed. The company aims to complete this study by the end of 2024, offering new hope for effective weight control treatments.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.